GPCR

Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Retrieved on: 
Tuesday, June 11, 2024

PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (GPCRs).

Key Points: 
  • GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis.
  • “As a result of our sustained efforts to develop this technology, Predictive Oncology has been able to file expansive intellectual property (IP) protection for its novel GPCR expression platform,” said Dr. Larry DeLucas, SVP of Biologics for Predictive Oncology.
  • The company believes this can overcome many of the difficulties seen with existing expression technologies.
  • “We are very pleased to introduce our new platform to potential pharma partners targeting GPCRs of interest,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology.

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares

Retrieved on: 
Friday, June 7, 2024

The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • The aggregate gross proceeds to Structure Therapeutics from the offering were approximately $547.4 million, before deducting underwriting discounts and commissions and offering expenses.
  • All of the ADSs were offered by Structure Therapeutics.
  • Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 5, 2024.

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Retrieved on: 
Thursday, June 6, 2024

SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS.

Key Points: 
  • SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $52.50 per ADS.
  • The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be approximately $476.0 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,360,045 ADSs at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on June 7, 2024, subject to the satisfaction of customary closing conditions.

Nimble Announces Formation of a World-Class Scientific Advisory Board

Retrieved on: 
Tuesday, June 11, 2024

Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.

Key Points: 
  • Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.
  • “We are honored to have these extraordinary scientific leaders join Nimble in its mission to create oral therapeutics to treat patients with immune-mediated diseases,” said Pete Gough, CSO of Nimble Therapeutics.
  • Luisa is a member of the Scientific Advisory Board of Anaptys, GPCR, Imimidomics and Attovia, and was previously on the SAB of Prometheus, Ambrx and Ventyx Bio and on the Board of Directors of Jounce Therapeutics.
  • Previously, Tomi was a Distinguished Scientist at Merck & Company, Founding Chief Scientific Officer at Aileron Therapeutics and Senior Vice-President of Drug Discovery at Ariad Pharmaceuticals (now Takeda).

Domain Therapeutics Strengthens Its Intellectual Property for Its Series of Treg Depleting anti-CCR8 Antibodies, Including Best-in-class Candidate DT-7012

Retrieved on: 
Thursday, June 6, 2024

These patents will significantly strengthen the Company’s intellectual property protection for its series of tumor-infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/ phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including DT-7012 , a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies.

Key Points: 
  • These patents will significantly strengthen the Company’s intellectual property protection for its series of tumor-infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/ phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including DT-7012 , a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies.
  • Currently in the pre-IND stage of development, DT-7012 is set to commence Phase I clinical trials in early 2025.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These three new patents are pivotal to our strategy, enhancing our robust patent estate and expanding our reach across diverse market opportunities.
  • They underscore the broad international application of our Treg depleting ADCC/ADCP anti-CCR8 antibodies, particularly for our lead anti-CCR8 candidate DT-7012.

Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

Retrieved on: 
Monday, June 3, 2024

Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.

Key Points: 
  • Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.
  • “Dan is an experienced public-company CFO who will add significant financial expertise to our team,” said Alise Reicin, MD, President and Chief Executive Officer of Tectonic.
  • Prior to joining Tectonic, he served as Chief Business Officer and Chief Financial Officer of Viatris' Eye Care Division following Viatris’ acquisition of Oyster Point Pharma, where he had previously served as Chief Financial Officer and Chief Business Officer.
  • “I’m honored to be joining the Tectonic team as it advances a pipeline of novel GPCR targeted biologic therapies.”
    Christian Cortis, Ph.D., the current Chief Operating Officer and Chief Financial Officer will be leaving the company to pursue external opportunities.

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Retrieved on: 
Monday, June 3, 2024

Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering.

Key Points: 
  • Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering.
  • In addition, Structure Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 ADSs at the public offering price, less the underwriting discounts and commissions.
  • The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 23, 2024

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced clinical data from the CHS-114, single agent dose escalation stage of its Phase 1 study at the ASCO Annual Meeting, taking place May 31 to June 4, 2024, at McCormick Place in Chicago. CHS-114 is a novel afucosylated human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that selectively and potently targets human CCR8 with no off-target binding. CCR8 is a G protein-coupled receptor (GPCR) that shows preferential expression on tumor resident Treg cells and has promise as a drug target for selectively targeting immune suppression in the tumor microenvironment (TME) without broadly depleting Treg cells, which has the known unwanted side effect of autoimmune activation.

Key Points: 
  • “The Phase 1 preliminary dose escalation results are an important milestone as we progress our innovative I-O pipeline.
  • Abstract # 2664: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114 (formerly SRF114) in Patients with Advanced Solid Tumors.
  • Preliminary results and acceptable safety profile support further evaluation of CHS-114 in combination treatment with toripalimab and other I-O agents.
  • In 19 patients evaluable for response, no objective responses were yet noted, while the stable disease rate was 47%.

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

Retrieved on: 
Monday, May 20, 2024

Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.

Key Points: 
  • Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.
  • “We are excited to present for the first time new preclinical findings from our breakthrough GPCR Native Complex Platform™ at ENDO 2024, marking a significant moment in our evolution to a clinical-stage company,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna.
  • “Led by our PTH1R program, which has the potential to be the first oral replacement therapy for hypoparathyroidism, these promising preclinical data validate our approach to discover novel GPCR-targeted medicines and reaffirm our dedication to deliver transformative therapies to patients in need of better treatment options.”
    Title: Characterization of a Novel Oral Small Molecule PTH1R Agonist: Proof of Concept for an Alternative to Injectable Peptide-based Therapy for Hypoparathyroidism
    Poster Session (P085): Bone and Mineral Metabolism: Clinical Osteoporosis
    Oral Abstract and Rapid-Fire Session (OR14): Bone and Mineral Metabolism: PTH, Calcium, and Phosphate Metabolism
    Presenter: Jun Zhang, Ph.D., Senior Director of Disease Biology, Septerna
    Presenter: Amer Mirza, Ph.D., Vice President, Disease Biology and Translational Sciences, Septerna

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Retrieved on: 
Thursday, May 9, 2024

SAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate achievements.

Key Points: 
  • High level PK study results are expected in June 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • The Company plans to initiate a Phase 2 study in T2DM in the second half of 2024.
  • R&D Expenses: Research and development (R&D) expenses for the first quarter of 2024 were $20.7 million, as compared to $13.1 million for the same period in 2023.